Point72 Asset Management
ACHL

Point72 Asset Management’s Achilles Therapeutics ACHL Stock Holding History

Point72 Asset Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,413,809
Closed -$1.26M – 2699
2023
Q4 		$1.26M Hold
1,413,809
– – ﹤0.01% 1336
2023
Q3 		$1.29M Hold
1,413,809
– – ﹤0.01% 1252
2023
Q2 		$1.34M Hold
1,413,809
– – ﹤0.01% 1094
2023
Q1 		$1.35M Hold
1,413,809
– – ﹤0.01% 1057
2022
Q4 		$1.27M Sell
1,413,809
-693,786
-33% -$1.17M ﹤0.01% 1010
2022
Q3 		$4.76M Buy
2,107,595
+330,851
+19% +$936K 0.02% 739
2022
Q2 		$4.48M Buy
1,776,744
+276,744
+18% +$683K 0.02% 738
2022
Q1 		$4.41M Buy
1,500,000
+500,000
+50% +$1.78M 0.02% 734
2021
Q4 		$5.01M Buy
1,000,000
+500,000
+100% +$3.03M 0.02% 669
2021
Q3 		$3.9M Buy
+500,000
New +$3.29M 0.02% 705

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Point72 Asset Management's ACHL Position: Q1 2024 in Review

Point72 Asset Management sold out of Achilles Therapeutics (ACHL) in Q1 2024, closing a stake of 1,413,809 shares — an estimated $1.26M sold.

Point72 Asset Management first reported a position in ACHL in Q3 2021 and held it in 10 quarters. The position peaked at $5.01M in Q4 2021. 32 funds tracked by Wall St. Rank hold ACHL as of Q1 2024.

  • Point72 Asset Management reported no remaining Achilles Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Asset Management sold 1,413,809 Achilles Therapeutics shares in Q1 2024, an estimated $1.26M.
  • Point72 Asset Management first reported a position in Achilles Therapeutics in Q3 2021 and held it in 10 quarters.
  • Point72 Asset Management's Achilles Therapeutics position peaked at $5.01M in Q4 2021.
  • 32 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2024.

Based on Point72 Asset Management's 13F filing for Q1 2024, filed 15 May 2024.